BioCancell is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer-related diseases. Its most advanced product candidate, BC-819, is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC). BC-819 will enter two Phase III confirmatory studies in 2016. BioCancell is also developing a second generation drug, BC-821 for the systemic treatment of advanced malignant neoplasms. Preclinical studies of BC-821 have showed significant efficacy in different cancer animal models such as metastatic lung cancer and metastatic liver cancer. BioCancell’s third product candidate, BC-830, is a “liquid biopsy,” which is intended to replace invasive and costly cystoscopies for the follow-up of NMIBC patients.
BioCancell’s R&D activities build upon the research of Professor Abraham Hochberg of the Hebrew University of Jerusalem. Professor Hochberg isolated the human H19 gene and determined that the gene is expressed in over forty different forms of cancer. H19-based therapy combines a highly selective method of killing cancer cells with a strong safety profile. Each of BioCancell’s product candidates relies on a proprietary H19 technology platform, with the potential to provide benefits that are competitive with existing cancer treatment methods.
In August, 2006, BioCancell successfully completed an initial public offering and its securities are now trading on the Tel Aviv Stock Exchange (TASE: BICL).
We are dedicated to the discovery, development and commercialization of safer, more effective treatment for cancer that address significant unmet medical needs and provide clinical benefits to millions of patients worldwide.
BioCancell’s core competencies are a robust scientific and technological base, dedicated and dynamic management team and strong IP position.
Scientific Stature – we are dedicated to the highest level of scientific innovation and research, while maintaining the strictest standards of ethics and integrity.